SHPH stock forecast, quote, news & analysis
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers... Show more
Why Shuttle Pharmaceuticals (SHPH) Stock Is Up +15% in the Last 30 Days
Key Takeaways
- Shuttle Pharmaceuticals (SHPH) rose roughly 15% over the last 30 days, climbing from about $4.71 on October 7, 2026, to $5.43 at the November 6 close.
- The advance extends a longer uptrend, with the stock up approximately 24% over the trailing three-month period.
- Investor attention has centered on the company's pivot toward AI-driven drug discovery through its Molecule.ai platform after winding down its Ropidoxuridine clinical trials in late 2025.
- As a micro-cap company with a limited float, SHPH carries above-average volatility, with sharp intraday swings amplifying short-term price moves.
- Elevated trading volume accompanied the October advance, reflecting renewed interest in AI-related biotechnology names.
- For deeper data, review Shuttle Pharmaceuticals' Price Targets, Earnings, and Forecast on Tickeron's dedicated pages.
- Explore Trending AI Robots to see automated strategies that may align with current market conditions.
Shuttle Pharmaceuticals (SHPH) Company Overview and Market Position
Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company headquartered in Gaithersburg, Maryland, and founded in 2012 by faculty members of the Georgetown University Medical Center. The company was originally built around radiation sensitizers — therapies designed to improve the effectiveness of radiation treatment for cancer patients — with a lead candidate, Ropidoxuridine (IPdR), developed for glioblastoma.
In November 2025, Shuttle acquired substantially all of the assets of Molecule.ai, an AI-driven platform for molecular discovery and early-stage drug development, and concurrently wound down its Ropidoxuridine clinical trials. This repositioned the company toward AI-augmented drug discovery. Investors follow SHPH because of its exposure to the intersection of artificial intelligence and oncology research, while also weighing its micro-cap size, limited operating resources, and early-stage profile.
Shuttle Pharmaceuticals (SHPH) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, SHPH advanced from a closing price of $4.71 on October 7, 2026, to $5.43 at the close on November 6, 2026 — a gain of approximately 15.3%. The move was not a straight line: the stock spiked toward $5.55 in early October before pulling back, and it recorded a notable intraday swing in late October when it traded as low as $3.30 before recovering.
The broader quarterly trend is similarly positive. At the start of August 2026, the stock was trading near $4.38, meaning the trailing three-month advance is roughly 24%. The overall pattern has been one of higher volatility and a generally upward bias, consistent with a micro-cap name drawing renewed investor interest.
What Drove SHPH Stock Price in the Last 30 Days
The recent move appears tied primarily to renewed investor interest in Shuttle's AI-driven drug discovery strategy. Following the Molecule.ai acquisition and the wind-down of its earlier clinical programs, the company has been repositioned around a computational platform that supports molecular property prediction and early-stage development. Enthusiasm for AI applications across healthcare and biotechnology has periodically lifted names with this profile.
Shuttle's market structure also amplifies price action. With roughly 4.76 million shares outstanding, a market capitalization in the tens of millions of dollars, and a small number of full-time employees, relatively modest shifts in trading activity can produce outsized percentage moves. Elevated volume around the October advance — including sessions exceeding 100,000 shares traded — is consistent with heightened speculative interest rather than a single company-specific announcement.
What Drove SHPH Stock Performance Over the Last Quarter
The quarterly gain reflects a longer narrative. Shuttle's November 2025 acquisition of Molecule.ai marked a strategic turning point, shifting the company from clinical-stage radiosensitizer development toward AI-enabled molecular discovery. This repositioning has also lowered operating costs; the company's research and development expenses declined sharply as the Ropidoxuridine trials wound down.
At the same time, broader market enthusiasm for artificial intelligence has created a favorable backdrop for small-cap companies claiming an AI angle, even when their commercial progress remains early stage. The combination of a strategic pivot, reduced clinical spending, and sector-level AI momentum has supported the stock's multi-month climb, punctuated by bouts of high volatility.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of automated trading strategies from a platform that hosts hundreds of AI-powered bots trading thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving traders a streamlined view of strategies currently generating notable results. The bots vary considerably in approach, holding timeframe, and performance metrics, allowing users to filter for styles that match their own objectives and risk tolerance. Monitoring this page can help traders identify quantitative strategies aligned with prevailing market conditions. Explore Trending AI Robots to see which automated strategies are drawing attention.
SHPH Stock Forecast Drivers: What Investors Should Watch Next
Investors monitoring SHPH should watch the company's upcoming quarterly earnings report and any updates on the commercialization and development of the Molecule.ai platform. Because the company generates minimal revenue and operates with limited cash, capital-raising activity and share-dilution risk remain central considerations for the outlook.
Broader developments in AI-driven healthcare — including regulatory stances on AI-assisted discovery and prescription tools — could influence sentiment across the sector. Finally, given SHPH's low float and thin trading volume, liquidity and volatility risks are likely to remain meaningful factors in near-term price behavior. None of this constitutes a prediction; the company's outlook depends on execution, funding, and market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for SHPH turns positive, indicating new upward trend
SHPH saw its Momentum Indicator move above the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 65 similar instances where the indicator turned positive. In 57 of the 65 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +5.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where SHPH advanced for three days, in 134 of 162 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 31 of 45 cases where SHPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Bearish Trend Analysis
The 10-day RSI Indicator for SHPH moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 similar instances where the indicator moved out of overbought territory. In 7 of the 8 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Moving Average Convergence Divergence Histogram (MACD) for SHPH turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 34 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SHPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
SHPH broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.349) is normal, around the industry mean (6.379). P/E Ratio (0.562) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. SHPH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SHPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric